| ²é¿´: 1186 | »Ø¸´: 4 | |||
zrmľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
¡¾ÇóÖú¡¿ÃÀ¹úÒ©µä33°æ ÒÑÓÐ3È˲ÎÓë
|
| ÓÐÃÀ¹úÒ©µä33°æµÄÄÜ·ñ°ïÎÒ²éÏÂË«±ûÎìËáÄÆµÄ±ê×¼£¬Ð»Ð»£¡£¡£¡£¡ |
» ²ÂÄãϲ»¶
WoSÒ»ÇøFrontiers in Genome Editing»ùÒò±à¼·½·¨ÓëÓ¦Ó÷½ÏòרÌâÑû¸å£¨Ó°ÏìÒò×Ó4.9£©
ÒѾÓÐ0È˻ظ´
Éú·À¾úµÄÅèÔÔ·ÀЧʵÑé
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ178È˻ظ´
Çë½Ì´óÀÐÀ©É¢ÎÊÌâ
ÒѾÓÐ5È˻ظ´
¹òÇóÒ»Ö§AAV293ϸ°û
ÒѾÓÐ1È˻ظ´
ÖÐÎÄͶ¸å¡°Ö×ÁöÃâÒß¡±Ïà¹Ø
ÒѾÓÐ6È˻ظ´
²©µ¼ÍƼö
ÒѾÓÐ2È˻ظ´
ÄÄÀï×ö¸Ê°±ËáÊÜÌåÓëÅäÌå½áºÏÂʵÄÊÔÑé
ÒѾÓÐ0È˻ظ´
2025ÄêҩѧרҵÇóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
292ҩѧµ÷¼Á
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÃÀ¹úÒ©µä¹ØÓÚÈðÊæ·¥ËûÍ¡¸ÆRosuvastatin CalciumµÄÖÊÁ¿±ê×¼
ÒѾÓÐ15È˻ظ´
ÃÀ¹úÒ©µäÀïµÄMºÍN´ú±íʲôµ¥Î»
ÒѾÓÐ8È˻ظ´
ÃÀ¹úÒ©µäUSP24 L-¼¡ëÄ
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú¡¿ÃÀ¹úÒ©µäÖÐÒ»¶ÎÔÎĵķÒëÎÊÌâ
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿×óÒÒÀÎ÷̹ ÃÀ¹úÒ©µä34°æ
ÒѾÓÐ9È˻ظ´
¡¾ÇóÖú¡¿´ó¼Ò°ïÎÒÕÒÃÀ¹úÒ©µäºÃÂð£¿
ÒѾÓÐ7È˻ظ´
¡¾ÇóÖú¡¿ÔõôÔÚÃÀ¹úÒ©µä²éÖÐÒ©±ê×¼£¿
ÒѾÓÐ7È˻ظ´
ÇóÃÀ¹úÒ©µä Brinzolamide ²¼ÁÖ×ô°·µç×Ó°æ ¼°·Òë
ÒѾÓÐ4È˻ظ´
¡¾ÇóÖú¡¿ÇóÖúAprepitant µÄÃÀ¹úÒ©µäÖÊÁ¿±ê×¼
ÒѾÓÐ6È˻ظ´
¹ØÓÚÃÀ¹úÒ©µäµÄÒÉÎÊ
ÒѾÓÐ4È˻ظ´
Ò»Ö»ºÃÈË
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 945.7
- É¢½ð: 30
- Ìû×Ó: 150
- ÔÚÏß: 53.6Сʱ
- ³æºÅ: 254901
- ×¢²á: 2006-05-27
- ÐÔ±ð: MM
- רҵ: ºÏ³ÉÒ©Îﻯѧ
2Â¥2011-08-04 09:57:50
Ò»Ö»ºÃÈË
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 945.7
- É¢½ð: 30
- Ìû×Ó: 150
- ÔÚÏß: 53.6Сʱ
- ³æºÅ: 254901
- ×¢²á: 2006-05-27
- ÐÔ±ð: MM
- רҵ: ºÏ³ÉÒ©Îﻯѧ
3Â¥2011-08-04 09:59:42
kongkong75
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1745
- ºì»¨: 3
- Ìû×Ó: 181
- ÔÚÏß: 41.6Сʱ
- ³æºÅ: 489534
- ×¢²á: 2008-01-02
- ÐÔ±ð: GG
- רҵ: ҩѧ
¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
warlen(½ð±Ò+1): лл²ÎÓë 2011-08-05 10:05:51
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
warlen(½ð±Ò+1): лл²ÎÓë 2011-08-05 10:05:51
|
Divalproex Sodium (dye val' proe ex soe' dee um) (C16H31NaO4)n 310.41 Pentanoic acid, 2-propyl-, sodium salt (2:1); Sodium hydrogen bis(2-propylvalerate) oligomer DEFINITION Divalproex Sodium contains NLT 98.0% and NMT 102.0% of available valproic acid (C8H16O2). IDENTIFICATION • A. Infrared Absorption 197K • B. Identification Tests¡ªGeneral, Sodium 191: Ignite 100 mg. ASSAY • Procedure Solution A: 3.5 g of monobasic sodium phosphate monohydrate in 900 mL of water. Adjust with phosphoric acid to a pH of 3.5. Dilute with water to 1 L. Mobile phase: Acetonitrile and Solution A (1:1) Standard stock solution: 5.0 µg/mL of USP Valproic Acid RS in Mobile phase Standard solution: 0.5 mg/mL of USP Valproic Acid RS, from Standard stock solution in Mobile phase Impurity stock solution: 0.5 mg/mL of USP Valproic Acid Related Compound A RS in acetonitrile System suitability solution: 0.5 mg/mL of valproic acid, from Standard stock solution, and 5 µg/mL of valproic acid related compound A, from Impurity stock solution, in Mobile phase Sample solution: 0.5 mg/mL of Divalproex Sodium in Mobile phase Chromatographic system (See Chromatography 621, System Suitability.) Mode: LC Detector: UV 215 nm Column: 4.6-mm ¡Á 15-cm; 5-µm packing L7 Flow rate: 1 mL/min Injection size: 20 µL System suitability Sample: System suitability solution [Note¡ªThe relative retention times for valproic acid related compound A and valproic acid are 0.69 and 1.0, respectively. ] Suitability requirements Resolution: NLT 5.0 between valproic acid related compound A and valproic acid Tailing factor: NMT 1.5 for the valproic acid peak Relative standard deviation: NMT 2.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of C8H16O2) in the portion of Divalproex Sodium taken: Result = (rU/rS) ¡Á (CS/CU) ¡Á (Mr1/Mr2) ¡Á (1/F) ¡Á 100 rU = = peak area from the Sample solution rS = = peak area from the Standard solution CS = = concentration of USP Valproic Acid RS in the Standard solution (mg/mL) CU = = concentration of the Sample solution (mg/mL) Mr1 = = molecular weight for divalproex sodium repeating unit, 310.41 Mr2 = = molecular weight for valproic acid, 144.21 F = = number of moles of valproic acid/mole of divalproex sodium repeating unit, 2 Acceptance criteria: 98.0%¨C102.0% IMPURITIES Inorganic Impurities • Heavy Metals, Method II 231: NMT 20 ppm SPECIFIC TESTS • Water Determination, Method I 921: NMT 1.0%, determined on 3.0 g ADDITIONAL REQUIREMENTS • Packaging and Storage: Preserve in tight containers. Store at room temperature • USP Reference Standards 11 USP Divalproex Sodium RS USP Valproic Acid RS USP Valproic Acid Related Compound A RS Auxiliary Information¡ª Please check for your question in the FAQs before contacting USP. Topic/Question Contact Expert Committee Monograph Ravi Ravichandran, Ph.D. Senior Scientist 1-301-816-8330 (MDPP05) Monograph Development-Psychiatrics and Psychoactives Reference Standards Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org USP33¨CNF28 Page 2830 Pharmacopeial Forum: Volume No. 32(6) Page 1675 Chromatographic Column¡ª DIVALPROEX SODIUM Chromatographic columns text is not derived from, and not part of, USP 33 or NF 28. |

4Â¥2011-08-04 21:41:14

5Â¥2012-07-19 10:14:22














»Ø¸´´ËÂ¥
10